M. Kaminiski

Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation.

K. Koral, K. Zasadny, M. Ljungberg, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

The iodine I-131 tositumomab therapeutic regimen: Summary of safety in 995 patients with relapsed/refractory low grade (LG) and transformed LG non-Hodgkin's lymphoma (NHL)

J. Armitage, A. Zelenetz, J. Leonard, 2004 .

Poor effectiveness of antenatal detection of fetal growth restriction and consequences for obstetric management and neonatal outcomes: a French national study

B. Blondel, J. Zeitlin, M. Kaminiski, 2015, BJOG : an international journal of obstetrics and gynaecology.

Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma (NHL).

J. Leonard, M. Kaminiski, B. Link, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted Therapies for Follicular Lymphoma

S. Carty, S. Malek, T. Phillips, 2021, Current Hematologic Malignancy Reports.